Angelo Di Leo is currently Head of the Sandro Pitigliani Medical Oncology Unit and Chair of the Oncology Department, at the Hospital of Prato, Istituto Toscano Tumori, Italy, a position which he took up in September 2003.
After graduating in medicine and surgery at the University of Palermo in 1988, he received his postgraduate diploma in medical oncology from the University of Pavia in 1992 and in 1996 he received his European certification in medical oncology. Dr Di Leo trained at the National Cancer Institute in Milan, where he worked for 7 years until 1996. From 1996 to 2003, he worked at the Chemotherapy Unit of the Jules Bordet Institute in Brussels, where in 1997 he was appointed senior staff member and Medical Director of the Breast European Adjuvant Studies Team.
Dr Di Leo’s main research interest is breast cancer and he has coordinated a number of international, pivotal Phase III trials in new adjuvant therapies. He is also heavily involved in the evaluation of molecular markers with potential predictive value to treat breast cancer patients.
Dr Di Leo is the author of many peer-reviewed articles and has lectured extensively at national and international meetings. He is a member of the Early Breast Cancer Trialists’ Cooperative Group steering committee, a member of the Scientific Advisory Council of the Susan G. Komen for the Cure®, and was a former member of the American Society of Clinical Oncology grants selection committee (2006–2009). He serves as member of the Breast International Group Executive Board, as ESMO Faculty Member (Breast Cancer) and as member of the ASCO Education Committee.